iPSC-F41

General

Cell Line

hPSCreg name NEIi004-A
Cite as:
NEIi004-A (RRID:CVCL_C1V0)
Alternative name(s)
iPSC-F41
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 11th February 2025
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator National institutes of Health (NEI)
Owner National Institutes of Health (NIH)

External Databases

BioSamples SAMEA12816322
Cellosaurus CVCL_C1V0
Wikidata Q114312504

General Information

* Is the cell line readily obtainable for third parties?
Yes
Cell line can only be used in: Research area
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46,XX
Karyotyping method: G-Banding

External Databases (Donor)

BioSamples SAMEA12816323

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. NEI/OGVFB/OGL
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Open Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell line name Human Skin fibroblast cells
Source cell type
Any primary mitochondrial disease in which the cause of the disease is monoallelic or biallelic variants in the OPA1 gene. While optic atrophy is present in most affected cases, OPA1 is a mitochondrial protein and thus features of this disease include abnormal mitochondrial morphology and multiple mitochondrial DNA deletions, and can affect other organ systems and. Extraocular features can include progressive sensorineural hearing impairment, cognitive impairment, peripheral neuropathy, myopathy, ragged-red muscle fibers, and exercise-induced lactic acidemia, while additional ocular features can include progressive visual loss, central scotoma, and color vision abnormalities.; Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found the molecular mechanism (loss of function variants in OPA1) to be consistent among apparently unrelated patients, while related patients harboring either biallelic or monoallelic OPA1 variants were affected with optic atrophy. The phenotypic variability between them appeared to represent a spectrum of disease rather than separate disease entities. Therefore, affected cases harboring monoallelic or biallelic OPA1 variants have been lumped into a single disease entity, referred to as OPA1-related optic atrophy with or without extraocular features.

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Medium Essential 8™ Flex
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SOX2
Yes
SSEA-4
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Morphology
IPSC-F41-Teratoma.pdf
Endoderm in teratoma assay
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
Morphology
IPSC-F41-Teratoma.pdf
Ectoderm in teratoma assay

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: 8

Other Genotyping (Cell Line)